128 related articles for article (PubMed ID: 21771995)
1. Reducing the long-term effects of chemotherapy in young women with early-stage breast cancer.
Rugo HS; Rosen MP
JAMA; 2011 Jul; 306(3):312-4. PubMed ID: 21771995
[No Abstract] [Full Text] [Related]
2. Gonadotropin-releasing hormone analogue for premenopausal women with breast cancer.
Loibl S; Gerber B
JAMA; 2011 Oct; 306(16):1760; author reply 1760-1. PubMed ID: 22028347
[No Abstract] [Full Text] [Related]
3. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
4. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma.
Falorio S; Angrilli F; Fioritoni G
Leuk Lymphoma; 2008 Jun; 49(6):1087-93. PubMed ID: 18452079
[TBL] [Abstract][Full Text] [Related]
5. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
[TBL] [Abstract][Full Text] [Related]
7. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma.
Blumenfeld Z; Dann E
J Clin Oncol; 2013 Oct; 31(29):3721. PubMed ID: 24002509
[No Abstract] [Full Text] [Related]
8. Reply to Z. Blumenfeld et al.
Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
J Clin Oncol; 2013 Oct; 31(29):3722-3. PubMed ID: 24002513
[No Abstract] [Full Text] [Related]
9. Strategies for fertility preservation in young early breast cancer patients.
Tomasi-Cont N; Lambertini M; Hulsbosch S; Peccatori AF; Amant F
Breast; 2014 Oct; 23(5):503-10. PubMed ID: 24934638
[TBL] [Abstract][Full Text] [Related]
10. Reproductive and hormonal sequelae of chemotherapy in women. Premature menopause and impaired fertility can result, effects that are especially disturbing to young women.
Knobf MT
Am J Nurs; 2006 Mar; 106(3 Suppl):60-5. PubMed ID: 16481857
[No Abstract] [Full Text] [Related]
11. Trying to reduce ovarian damage in patients with Hodgkin lymphoma using GnRH agonists?
Oktay K; Sonmezer M; Barad D; Gleicher N
Fertil Steril; 2009 Jan; 91(1):298-9; author reply 299. PubMed ID: 19046580
[No Abstract] [Full Text] [Related]
12. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin.
Meattini I; Saieva C; Meacci F; Scotti V; De Luca Cardillo C; Desideri I; Baldazzi V; Mangoni M; Scoccianti S; Detti B; Simontacchi G; Nori J; Orzalesi L; Sanchez L; Casella D; Bernini M; Fambrini M; Bianchi S; Livi L
Future Oncol; 2016 Mar; 12(5):625-35. PubMed ID: 26837239
[TBL] [Abstract][Full Text] [Related]
13. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD).
Giuseppe L; Attilio G; Edoardo DN; Loredana G; Cristina L; Vincenzo L
Hematology; 2007 Apr; 12(2):141-7. PubMed ID: 17454195
[TBL] [Abstract][Full Text] [Related]
14. [Premature ovarian failure in patients affected by oncohematological disease].
Marchesoni D; Driul L; Fruscalzo A; Santuz M; Calcagno A; Ianni A; Geromin A; Fanin R
Minerva Ginecol; 2005 Oct; 57(5):545-50. PubMed ID: 16205599
[TBL] [Abstract][Full Text] [Related]
15. 3-month triptorelin in premenopausal patients with hormone receptor-positive early breast cancer: a commentary and a retrospective experience.
Caruso M; Castiglione G; Aiello R; Alí M; Chiarenza M; Dimarco R; Fallica G; Di Leo MG; Sanó MV; Taibi E; Zacchia A; Miano E; Caruso F
Future Oncol; 2015; 11(23):3109-12. PubMed ID: 26544787
[No Abstract] [Full Text] [Related]
16. Triptorelin: A Review of its Use as an Adjuvant Anticancer Therapy in Early Breast Cancer.
Frampton JE
Drugs; 2017 Dec; 77(18):2037-2048. PubMed ID: 29177573
[TBL] [Abstract][Full Text] [Related]
17. Impact of breast cancer treatment on fertility.
de la Haba-Rodríguez J; Calderay M
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():59-63. PubMed ID: 20711656
[No Abstract] [Full Text] [Related]
18. [Role of ovarian suppression in the combined treatment of breast cancer patients in premenopause].
Shchepotin IB; Zotov AS; Liubota RV; Anikus'ko NF; Liubota II
Vopr Onkol; 2013; 59(3):397-404. PubMed ID: 23909046
[No Abstract] [Full Text] [Related]
19. Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.
Brunner HI; Silva CA; Reiff A; Higgins GC; Imundo L; Williams CB; Wallace CA; Aikawa NE; Nelson S; Klein-Gitelman MS; Rose SR
Arthritis Rheumatol; 2015 May; 67(5):1377-85. PubMed ID: 25676588
[TBL] [Abstract][Full Text] [Related]
20. [Ovarian stimulation using a protocol of low dose agonist in patients with an elevated basal FSH].
Olivennes F; Righini C; Fanchin R; Torrisi C; Hazout A; Glissant M; Fernandez H; Frydman R
Contracept Fertil Sex; 1996 Dec; 24(12):912-6. PubMed ID: 9026280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
